Health Care

Veeva’s Q2 2026 earnings hit a record 40% jump in operating income, sparking analyst target hikes to $275‑$325 and a new 52‑week high in shares.

BCG

EssilorLuxottica launches a $918 M buyback and new vision tech, boosting investor confidence while tackling the 2050 myopia crisis.

NeuroOne’s recent insider buys show exec confidence in its EEG and brain‑stimulation tech, highlighting strong growth potential in medical devices.

Explore CollPlant Biotechnologies, a Nasdaq‑listed biotech pushing 3D bioprinting for tissue repair and orthobiologics amid market volatility and future‑focused innovation.

Pro‑Dex’s latest SEC 8‑K reveals key leadership changes, executive bonuses, and fresh growth strategy—insights for investors in the healthcare equipment sector.

BioCryst’s Japan approval for pediatric hereditary angioedema marks a milestone, expanding rare‑disease care and positioning the biotech firm for future global filings.

Explore how Novo Nordisk’s looming patent cliffs, new weight‑loss and hair‑loss opportunities, and defensive market status shape its future strategy.

Tenax Therapeutics to reveal Phase‑3 LEVEL study results for TNX‑103 at ESC 2026, showing a 55‑meter 6MWD gain and solid safety in PH‑HFpEF.

Legend Biotech’s fall from a $37.50 high to $19.88, a negative P/E of -41.05, raises red flags on its cell‑therapy promise and investor confidence.